Connection
Amit Tiwari to Neoplasms
This is a "connection" page, showing publications Amit Tiwari has written about Neoplasms.
|
|
Connection Strength |
|
|
|
|
|
3.041 |
|
|
|
-
Sharma R, Tiwari AK. Bridging racial and ethnic disparities in cancer research. Cancer Rep (Hoboken). 2023 09; 6 Suppl 1:e1871.
Score: 0.437
-
Amawi H, Al-Azzam S, Alzanati T, Altamimi N, Hammad A, Alzoubi KH, Ashby CR, Tiwari AK. The Validity of Mobile Applications to Facilitate Patient Care Provided to Cancer Patients: Opportunities and Limitations. Recent Pat Anticancer Drug Discov. 2022; 17(2):204-213.
Score: 0.392
-
Tiwari AK. Transformative Approaches to Improve Chemotherapy for Difficult to Treat Solid Tumors. Curr Pharm Des. 2021; 27(46):4649.
Score: 0.366
-
Namdeo AG, Boddu SHS, Amawi H, Ashby CR, Tukaramrao DB, Trivedi P, Babu RJ, Tiwari AK. Flavonoids as Multi-Target Compounds: A Special Emphasis on their Potential as Chemo-adjuvants in Cancer Therapy. Curr Pharm Des. 2020; 26(15):1712-1728.
Score: 0.341
-
Amawi H, Ashby CR, Tiwari AK. Cancer chemoprevention through dietary flavonoids: what's limiting? Chin J Cancer. 2017 Jun 19; 36(1):50.
Score: 0.286
-
Robey RW, Fitzsimmons CM, Guiblet WM, Frye WJE, Gonz?lez Dalmasy JM, Wang L, Russell DA, Huff LM, Perciaccante AJ, Ali-Rahmani F, Lipsey CC, Wade HM, Mitchell AV, Maligireddy SS, Terrero D, Butcher D, Edmondson EF, Jenkins LM, Nikitina T, Zhurkin VB, Tiwari AK, Piscopio AD, Totah RA, Bates SE, Arda HE, Gottesman MM, Batista PJ. The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors. Mol Cancer Ther. 2024 Apr 02; 23(4):464-477.
Score: 0.115
-
Shirbhate E, Singh V, Kore R, Vishwakarma S, Veerasamy R, Tiwari AK, Rajak H. The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance. Curr Top Med Chem. 2024; 24(6):523-540.
Score: 0.113
-
Shirbhate E, Singh V, Mishra A, Jahoriya V, Veerasamy R, Tiwari AK, Rajak H. Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer. Mini Rev Med Chem. 2024; 24(15):1449-1468.
Score: 0.113
-
Shirbhate E, Singh V, Jahoriya V, Mishra A, Veerasamy R, Tiwari AK, Rajak H. Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment. Eur J Med Chem. 2024 Jan 05; 263:115938.
Score: 0.111
-
Ji N, Tiwari AK, Yang DH. Unraveling immunotherapy's role in propelling cancer outcomes. Cancer Rep (Hoboken). 2023 07; 6(7):e1862.
Score: 0.109
-
Shirbhate E, Veerasamy R, Boddu SHS, Tiwari AK, Rajak H. Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment. Drug Discov Today. 2022 06; 27(6):1689-1697.
Score: 0.099
-
Deng LJ, Deng WQ, Fan SR, Chen MF, Qi M, Lyu WY, Qi Q, Tiwari AK, Chen JX, Zhang DM, Chen ZS. m6A modification: recent advances, anticancer targeted drug discovery and beyond. Mol Cancer. 2022 02 14; 21(1):52.
Score: 0.099
-
Kabir MA, Kharel A, Malla S, Kreis ZJ, Nath P, Wolfe JN, Hassan M, Kaur D, Sari-Sarraf H, Tiwari AK, Ray A. Automated detection of apoptotic versus nonapoptotic cell death using label-free computational microscopy. J Biophotonics. 2022 04; 15(4):e202100310.
Score: 0.098
-
Alrbyawi H, Poudel I, Annaji M, Arnold RD, Tiwari AK, Babu RJ. Recent Advancements of Stimuli-Responsive Targeted Liposomal Formulations for Cancer Drug Delivery. Pharm Nanotechnol. 2022; 10(1):3-23.
Score: 0.098
-
Balaji S, Terrero D, Tiwari AK, Ashby CR, Raman D. Alternative approaches to overcome chemoresistance to apoptosis in cancer. Adv Protein Chem Struct Biol. 2021; 126:91-122.
Score: 0.093
-
Annaji M, Poudel I, Boddu SHS, Arnold RD, Tiwari AK, Babu RJ. Resveratrol-loaded nanomedicines for cancer applications. Cancer Rep (Hoboken). 2021 06; 4(3):e1353.
Score: 0.092
-
Amawi H, Sim HM, Tiwari AK, Ambudkar SV, Shukla S. ABC Transporter-Mediated Multidrug-Resistant Cancer. Adv Exp Med Biol. 2019; 1141:549-580.
Score: 0.080
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|